Technical Analysis for PYXS - Pyxis Oncology, Inc.

Grade Last Price % Change Price Change
C 11.19 -3.53% -0.41
PYXS closed down 1.44 percent on Monday, October 18, 2021, on 38 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical PYXS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -3.53%
Hot IPO Pullback Bullish Swing Setup -3.53%
Inside Day Range Contraction -3.53%
Down 3 Days in a Row Weakness -3.53%
New 52 Week Closing Low Bearish -4.93%
Hot IPO Pullback Bullish Swing Setup -4.93%
Outside Day Range Expansion -4.93%
Inside Day Range Contraction -5.41%
New 52 Week Closing Low Bearish -5.01%
Hot IPO Pullback Bullish Swing Setup -5.01%
Older End-of-Day Signals for PYXS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 1 hour ago
Up 1% about 1 hour ago
60 Minute Opening Range Breakdown about 2 hours ago
Down 3% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Clinical Medicine Immunology Solid Tumors Immunotherapy Cancers Monoclonal Antibody Cancer Treatments Non Small Cell Lung Cancer Acute Myeloid Leukemia Small Cell Lung Cancer Immunotherapies Antineoplastic Drugs Treatment Of Non Small Cell Lung Cancer Treatment Of Acute Myeloid Leukemia Blood Cancers Soft Tissue Sarcoma Antibody Drug Conjugate

Is PYXS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.0
52 Week Low 10.93
Average Volume 521,965
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.64
Resistance 3 (R3) 12.66 12.33 12.47
Resistance 2 (R2) 12.33 12.06 12.32 12.41
Resistance 1 (R1) 11.97 11.90 11.80 11.95 12.35
Pivot Point 11.64 11.64 11.55 11.63 11.64
Support 1 (S1) 11.27 11.37 11.11 11.25 10.85
Support 2 (S2) 10.94 11.21 10.93 10.79
Support 3 (S3) 10.58 10.94 10.73
Support 4 (S4) 10.56